Genzyme Tissue Repair (GZTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Linda Kaplan who wrote (1981)	7/13/1998 2:05:00 PM
From: Machaon	Read Replies (1) of 2553

They mentioned ORG and ATIS. The most interesting part, for me, was the estimate of 1 - 1.5 million burn victims, each year, that could benefit from the skin grafts. That is quite a large market. No wonder why there are so many companies involved! GENZL has a head start. They reduced the growth time, significantly, to only 16 days. This may sound like a broken record, but, it'll be interesting to see how much of that 1-1.5 million patient market GENZL picks up due to the reduction in time to grow Epicel. Good luck, Bob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next